Synucure Therapeutics inc. is a Canadian biotechnology company conducting research in brain degenerative disorders. Synucure was founded in 2021 with the key objective to pursue the promising and robust pre-clinical work of Dr. Francesca Cicchetti on a repurposed drug called Cysteamine which demonstrated, in various animal and cell models, that it could prevent and/or reverse a number of features related to Parkinson’s disease (PD). 

In addition to the promising role of Cysteamine as a Disease Modifying Therapy (DMT), Dr. Cicchetti and her colleagues are conducting research on patented blood biomarkers, of which the primary goal is to provide clinicians, patients, and the industry with an additional diagnostic tool for a more precise detection of Parkinson’s disease via simple blood test.